For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| License revenue | - | - | - | 0 |
| Research and development | 77,889,000 | 70,112,000 | 63,497,000 | 39,617,000 |
| General and administrative | 32,235,000 | 31,759,000 | 39,061,000 | 22,412,000 |
| Total operating expenses | 110,124,000 | 101,871,000 | 102,558,000 | 62,029,000 |
| Loss from operations | -110,124,000 | -101,871,000 | -102,558,000 | -62,029,000 |
| Interest income | 14,591,000 | 13,289,000 | 12,901,000 | 2,110,000 |
| Other expense, net | -93,000 | -11,000 | -314,000 | -68,000 |
| Total other income, net | 14,498,000 | 13,278,000 | 12,587,000 | 2,042,000 |
| Loss before income taxes | -95,626,000 | -88,593,000 | -89,971,000 | -59,987,000 |
| Income tax expense | 581,000 | 260,000 | 239,000 | 358,000 |
| Net loss | -96,207,000 | -88,853,000 | -90,210,000 | -60,345,000 |
| Unrealized gain (loss) on available-for-sale securities, net of tax | - | -235,000 | 671,000 | -320,000 |
| Foreign exchange translation adjustment, net of tax | - | -25,000 | 132,000 | -164,000 |
| Comprehensive loss | - | -89,113,000 | -89,407,000 | -60,829,000 |
| Basic EPS | -1.03 | -1.12 | -1.27 | -1.67 |
| Diluted EPS | -1.03 | -1.12 | -1.27 | -1.67 |
| Basic Average Shares | 93,166,571 | 79,507,474 | 71,259,239 | 36,033,045 |
| Diluted Average Shares | 93,166,571 | 79,507,474 | 71,259,239 | 36,033,045 |
Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. (TERN)